pyrazines has been researched along with Lymphoma, B-Cell in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (37.21) | 29.6817 |
| 2010's | 23 (53.49) | 24.3611 |
| 2020's | 4 (9.30) | 2.80 |
| Authors | Studies |
|---|---|
| Barr, PM; Calvo, R; Melear, JM; O'Brien, SM; Patel, P; Roschewski, MJ; Sharman, JP; Smith, SD; Spurgeon, SE; Yang, H | 1 |
| Chong, EA; Davids, MS; Mato, AR; Roeker, LE; Schuster, SJ; Shadman, M | 1 |
| Bhargava, P; Bouabdallah, K; Cartron, G; Danilov, AV; Davies, AJ; Dyer, MJS; Fegan, C; Hodson, DJ; Huang, X; Humeniuk, R; Jürgensmeier, JM; Li, B; Morschhauser, F; Radford, J; Rajakumaraswamy, N; Rule, SA; Salles, G; Spurgeon, S; Walter, HS; Ysebaert, L | 1 |
| Corneth, OBJ; de Bruijn, MJW; Hendriks, RW; Neys, SFH; Rip, J; Singh, SP; van Hulst, JAC; Willar, J | 1 |
| Liu, Y; Ran, F; Wang, ML; Yang, D; Zhang, D; Zhang, Z; Zhao, G | 1 |
| da Cunha-Bang, C; Niemann, CU | 1 |
| Bernasconi, E; Bertoni, F; Cascione, L; Dirnhofer, S; Gaudio, E; Gerlach, MM; Mascia, M; Priebe, V; Spriano, F; Stathis, A; Tarantelli, C; Targa, A; Zucca, E | 1 |
| Czuczman, MS; Czuczman, NM; Gu, JJ; Hernandez-Ilizaliturri, FJ; Kaufman, GP; Mavis, C; Skitzki, JJ | 1 |
| Blum, KA; Maddocks, K | 1 |
| Delić, J; Gobec, M; Markovič, T; Mlinarič-Raščan, I; Prijatelj, M | 1 |
| Barth, MJ; Czuczman, MS; Frys, S; Gu, JJ; Hernandez-Ilizaliturri, FJ; Hu, Q; Mavis, C; Simons, Z; Skitzki, J; Song, L | 1 |
| Aherne, GW; Box, G; Boxall, KJ; Collins, I; De Haven Brandon, AK; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Henley, AT; Hunter, JE; Lainchbury, M; Matthews, TP; McHardy, T; Osborne, J; Perkins, ND; Raynaud, FI; Reader, JC; Swales, K; Tall, M; Valenti, MR; Walton, MI | 1 |
| Agrawal, SG; Gribben, JG; Jia, L; Liu, FT; Movasaghi, Z; Newland, AC; Rehman, IU; Wyatt, PB | 1 |
| Bonavida, B; Huerta-Yepez, S; Jazirehi, AR; Martinez-Maza, O; Martinez-Paniagua, M; Umezawa, K; Vega, MI | 1 |
| Brice, P; Briere, J; Ertault, M; Ferme, C; Gisselbrecht, C; Golfier, JB; Haioun, C; Mounier, N; Ribrag, V; Salles, G | 1 |
| Belardo, G; Piva, R; Santoro, MG | 1 |
| Asmar, L; Barrera, D; Boehm, KA; Boston, J; Boyd, T; Cochran, EW; Di Bella, N; Dien, PY; Kolibaba, K; Lyons, R; Raju, R; Schlegel, PJ; Taetle, R; Vukelja, SJ; Wang, Y | 1 |
| Blumel, S; Butos, J; Cooper, B; Dumitrescu, O; Evens, AM; Gerecitano, J; Gonen, M; Hamlin, P; Mac-Gregor Cortelli, B; Moskowitz, C; Neylon, E; O'Connor, OA; Portlock, C; Sarasohn, D; Straus, D; Vose, J; Winter, J; Wright, J; Zelenetz, AD | 1 |
| Basak, GW; Bil, J; Bojarczuk, K; Dabrowska-Iwanicka, A; Golab, J; Jakobisiak, M; Nowis, D; Sułek, K; Winiarska, M | 1 |
| Bangia, N; Belicha-Villanueva, A; Blickwedehl, J; Clements, JL; Czuczman, MS; Gibbs, J; Hernandez-Ilizaliturri, FJ; Mavis, C; Olejniczak, SH; Riaz, W | 1 |
| Cheung, YK; Lee, SM | 1 |
| Coppola, D; Dawson, J; Doyle, A; Figg, WD; Grant, S; Hogan, KT; Holkova, B; Kang, L; Kolla, S; Peer, C; Perkins, EB; Ramakrishnan, V; Roberts, JD; Roodman, GD; Shrader, E; Stuart, RK; Sullivan, DM; Talreja, N; Tombes, MB; Wellons, MD; Wright, J | 1 |
| Beaven, AW; Feldman, T; Ferraro, M; Ford, P; Goy, A; Ivanova, A; Moore, DT; Shea, TC; Smith, J | 1 |
| Ohmachi, K | 1 |
| Bannerman, B; Bano, K; Berger, AJ; Bolen, JB; Bradley, DP; Carsillo, M; Donelan, J; Fitzgerald, M; Hales, P; Janz, S; Kupperman, E; Lee, EC; Li, P; Li, Z; Liu, R; Manfredi, M; Neppalli, VT; Pickard, M; Silva, MD; Subakan, O; Tayber, O; Terkelsen, J; Van Ness, B | 1 |
| Goel, A; Spitz, DR; Weiner, GJ | 1 |
| Cheson, BD; Koprivnikar, JL | 1 |
| Bumpers, K; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; Kaufman, JL; Khoury, HJ; King, N; Lechowicz, MJ; Lewis, C; Lonial, S; Shenoy, PJ; Sinha, R; Tighiouart, M | 1 |
| Ogura, M | 1 |
| Bernstein, SH; de Vos, S; Esseltine, DL; Fisher, RI; Goy, A; Morrison, VA; Neuwirth, R; Solh, M | 1 |
| Schenkein, D | 1 |
| Ford, RJ; Lo, P; Pham, LV; Tamayo, AT; Yoshimura, LC | 1 |
| Jäger, U | 1 |
| Broglio, K; Cabanillas, F; Dang, NH; Fayad, L; Gilles, F; Goy, A; Hagemeister, F; Hart, S; McLaughlin, P; Pro, B; Rodriguez, AM; Romaguera, JE; Samaniego, F; Samuels, B; Sarris, AH; Schenkein, D; Trehu, E; Wang, M; Younes, A | 1 |
| Andtbacka, R; McConkey, D; Nawrocki, ST | 1 |
| Bohlius, J; Engert, A; Hülsewede, H; Kober, T | 1 |
| Chan, KK; Chanan-Khan, A; Frankel, S; Liu, S; Marcucci, G; O'Connor, OA; Rolfe, M; Smith, EA; Teruya-Feldstein, J; Toner, LE; Wei, X | 1 |
| Nguyen, CA; Romaguera, J; Wang, M; Zhang, L; Zhou, Y | 1 |
| Anderson, KC; Bhole, D; Burger, R; Catley, L; Chauhan, D; Galardy, P; Hideshima, T; Kessler, B; Mitsiades, C; Munshi, NC; Ploegh, H; Podar, K; Shringarpure, R; Tai, YT; Tassone, P | 1 |
| Burton, AW; Cata, JP; Dougherty, PM; Giralt, S; Villareal, H; Weng, HR | 1 |
| Allen, P; Higginbottom, K; Joel, SP; Jüliger, S; Lister, TA; Maharaj, L; Schenkein, D; Strauss, SJ | 1 |
| Binder, A; Czuczman, MS; Deans, J; Gowda, A; Hernandez-Ilizaliturri, FJ; Kaur, H; Knight, J; Kotowski, A; Olejniczak, S; Starostik, P | 1 |
8 review(s) available for pyrazines and Lymphoma, B-Cell
| Article | Year |
|---|---|
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Autoimmune Diseases; Benzamides; Drug Design; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines | 2018 |
Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Benzamides; Drug Therapy, Combination; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2018 |
Ibrutinib in B-cell Lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thalidomide; Treatment Outcome | 2014 |
[Present status and perspective of targeted therapy for B-cell lymphoma].
Topics: Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Discovery; Flavonoids; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Piperidines; Protease Inhibitors; Protein Kinase C; Protein Kinase C beta; Protein-Tyrosine Kinases; Pyrazines; Rituximab; Thalidomide; Vorinostat | 2011 |
Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lymphoma, B-Cell; Multiple Myeloma; Oxidation-Reduction; Oxidative Stress; Oxides; Pyrazines; Radiotherapy | 2012 |
Proteasome inhibitors in the treatment of B-cell malignancies.
Topics: Acetylcysteine; Animals; Boronic Acids; Bortezomib; Cell Cycle Proteins; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzymes; Gene Expression Regulation; Hodgkin Disease; Humans; Leukemia, B-Cell; Leupeptins; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Oncogene Proteins; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Substrate Specificity; Transcription Factors; Treatment Outcome | 2002 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Europe; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Multicenter Studies as Topic; Multiple Myeloma; National Institutes of Health (U.S.); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Procarbazine; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; United States; Vinblastine; Vincristine | 2006 |
Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma; Pyrazines; Waldenstrom Macroglobulinemia | 2006 |
10 trial(s) available for pyrazines and Lymphoma, B-Cell
| Article | Year |
|---|---|
Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.
Topics: Adenosine; Benzamides; Humans; Lymphoma, B-Cell; Phosphatidylinositol 3-Kinases; Pyrazines; Quinolines | 2022 |
Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Imidazoles; Indazoles; Lymphoma, B-Cell; Male; Middle Aged; Protein Kinase Inhibitors; Purines; Pyrazines; Pyrimidines; Quinazolinones | 2021 |
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Prednisone; Pyrazines; Rituximab; Vincristine | 2009 |
Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Treatment Outcome | 2010 |
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Pyrazines; Recurrence; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Piperidines; Pyrazines; Recurrence; Treatment Failure | 2011 |
A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Radioimmunotherapy; Salvage Therapy; Survival Rate | 2012 |
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neural Conduction; Prednisone; Pyrazines; Rituximab; Vincristine | 2012 |
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Protease Inhibitors; Pyrazines; Survival Rate; Treatment Outcome | 2005 |
25 other study(ies) available for pyrazines and Lymphoma, B-Cell
| Article | Year |
|---|---|
BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Inflammation; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Macrophages; Pandemics; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; SARS-CoV-2 | 2020 |
Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B-Lymphocytes; Benzamides; CD79 Antigens; Extracellular Signal-Regulated MAP Kinases; Immunoglobulin M; Lymphoma, B-Cell; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B; Phosphatidylinositol 3-Kinases; Phospholipase C gamma; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Receptors, Antigen, B-Cell; Signal Transduction; Syk Kinase | 2021 |
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
Topics: Adenosine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice, SCID; Protein Kinase Inhibitors; Pyrazines; Quinolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cell Cycle Checkpoints; Cytotoxicity, Immunologic; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Lymphoma, B-Cell; Neoplasm Proteins; Oligopeptides; Proteasome Inhibitors; Pyrazines; Rituximab; Tumor Cells, Cultured; Up-Regulation | 2013 |
Chemo-sensitizing effects of EP4 receptor-induced inactivation of nuclear factor-κB.
Topics: Alprostadil; Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Burkitt Lymphoma; Caspases; Cell Line, Tumor; Doxorubicin; Humans; Jurkat Cells; Leukemia, B-Cell; Lymphoma, B-Cell; NF-kappa B; Pyrazines; Receptors, Prostaglandin E, EP4 Subtype; Signal Transduction; U937 Cells | 2014 |
Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cytarabine; Drug Resistance, Neoplasm; Female; G1 Phase Cell Cycle Checkpoints; Histone Deacetylase Inhibitors; Humans; Lymphoma, B-Cell; Male; Mice; Mice, SCID; Pyrazines; Pyridines; Rituximab; Xenograft Model Antitumor Assays | 2015 |
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Topics: 4-Aminopyridine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cyclin-Dependent Kinases; Deoxycytidine; DNA Damage; Drug Synergism; Gemcitabine; HT29 Cells; Humans; Irinotecan; Lung Neoplasms; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Pyrazines; Xenograft Model Antitumor Assays | 2016 |
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Boric Acids; Boronic Acids; Bortezomib; Cell Line, Transformed; Cell Line, Tumor; Cytochromes c; Diet; Flavonoids; Free Radical Scavengers; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Multiple Myeloma; Protease Inhibitors; Pyrazines; Quercetin | 2008 |
The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclohexanones; Drug Resistance, Neoplasm; Humans; Lymphoma, AIDS-Related; Lymphoma, B-Cell; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Rituximab | 2008 |
Heat stress triggers apoptosis by impairing NF-kappaB survival signaling in malignant B cells.
Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA; DNA-Binding Proteins; Heat Shock Transcription Factors; Heat-Shock Response; Hot Temperature; Humans; Inhibitor of Apoptosis Proteins; Lymphoma, B-Cell; NF-kappa B; Protein Biosynthesis; Pyrazines; Signal Transduction; Transcription Factor RelA; Transcription Factors; Ubiquitin-Protein Ligases | 2010 |
Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Biotinylation; Blotting, Western; Boronic Acids; Bortezomib; Cells, Cultured; Cytotoxicity, Immunologic; Flow Cytometry; Humans; Immunoprecipitation; Lymphoma, B-Cell; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Rituximab; RNA, Messenger | 2010 |
Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Immunoprecipitation; Lymphoma, B-Cell; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Cells, Cultured; Ubiquitination | 2010 |
Calibration of prior variance in the Bayesian continual reassessment method.
Topics: Algorithms; Antineoplastic Agents; Bayes Theorem; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Humans; Lymphoma, B-Cell; Maximum Tolerated Dose; Models, Statistical; Pyrazines | 2011 |
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
Topics: Animals; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Glycine; Humans; Lymphoma, B-Cell; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Neoplasms, Plasma Cell; Osteolysis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2011 |
Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Proteasome Inhibitors; Pyrazines; Recurrence | 2012 |
Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Herpes Zoster; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Pyrazines; Recurrence; Risk Factors | 2013 |
Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocyte Subsets; bcl-X Protein; Biopsy; Boronic Acids; Bortezomib; Cell Cycle; Growth Inhibitors; Humans; Hydrolysis; I-kappa B Proteins; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Minor Histocompatibility Antigens; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Organic Chemicals; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfones; Tumor Cells, Cultured | 2003 |
Innovative strategies in lymphoma therapy.
Topics: Alemtuzumab; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Forecasting; Genetic Therapy; Humans; Immunoconjugates; Immunotherapy; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Prednisone; Protease Inhibitors; Proteomics; Pyrazines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Rituximab; Signal Transduction; Survival Analysis; Thalidomide; Time Factors; Vincristine | 2003 |
Velcade displays promising activity in primary effusion lymphoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Humans; Lymphoma, B-Cell; Pleural Effusion, Malignant; Pyrazines | 2005 |
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
Topics: Animals; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Genes, bcl-2; Humans; Kinetics; Lymphoma, B-Cell; Mice; Mice, SCID; Oligonucleotides, Antisense; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thionucleotides; Transplantation, Heterologous | 2006 |
Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Polymerase Chain Reaction; Proteasome Inhibitors; Pyrazines; TCF Transcription Factors; Transcription Factor 7-Like 2 Protein; Tumor Cells, Cultured | 2006 |
Quantitative sensory findings in patients with bortezomib-induced pain.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Cold Temperature; Female; Hot Temperature; Humans; Lymphoma, B-Cell; Male; Middle Aged; Multiple Myeloma; Pain; Pain Measurement; Pain Threshold; Psychomotor Performance; Pyrazines; Sensation; Sensation Disorders; Thermosensing; Touch | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Enzyme Activation; Humans; Lymphoma, B-Cell; Mitosis; NF-kappa B; Nitriles; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfones; Tumor Suppressor Protein p53 | 2007 |
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Calcium; Down-Regulation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Humans; Immunoglobulins; Lymphoma, B-Cell; Membrane Microdomains; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Rituximab; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured | 2008 |